According to a recent LinkedIn post from Astraveus, the company plans to participate in the Cell & Gene Therapy Summit at ChinaBio in Shanghai on April 28–29, marking its first congress presence in China. The post notes that CEO and founder Jérémie Laurent will present an overview of Lakhesys™, a microfluidics-based all‑in‑one cell therapy manufacturing platform, focusing on how microfluidic bioprocessing could address bottlenecks from discovery to commercialization.
Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
The post also indicates that Business Development Specialist Paul Cochard-Marchewka, PhD, will present new data on a bench‑size microfluidic “cell factory” designed to optimize and scale CAR‑T manufacturing. By emphasizing engagement with China’s rapidly growing cell and gene therapy ecosystem, the content suggests Astraveus may be exploring partnership, commercialization, and market‑entry opportunities that could support longer‑term revenue prospects and enhance its positioning in advanced therapy manufacturing.
The company’s role as a sponsor of the event, as referenced in the post, may help increase visibility among Chinese and global biopharma stakeholders active in cell therapy. For investors, this outreach could signal strategic intent to integrate into a key global hub for cell and gene therapy innovation and manufacturing, potentially accelerating validation of the Lakhesys™ platform and broadening the addressable customer base if collaborations or pilot projects emerge over time.